{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:51:25Z","timestamp":1791924685430,"version":"4.3.4"},"reference-count":39,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The Proviral Integration site for the Moloney murine leukemia virus (PIM)-1 kinase and its family members (PIM-2 and PIM-3) regulate several cellular functions including survival, proliferation, and apoptosis. Recent studies showed their involvement in the pathogenesis of rheumatoid arthritis RA, while no studies are available on psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). The main objective of this study is to assess the expression of PIM kinases in inflammatory arthritides, their correlation with proinflammatory cytokines, and their variation after treatment with biologic disease-modifying anti-rheumatic drugs or JAK inhibitors. We evaluated PIM-1, -2, and -3 expression at the gene and protein level, respectively, in the peripheral blood mononuclear cells and serum of patients with RA, PsA, axSpA, and healthy individuals (CTR). All the samples showed expression of PIM-1, -2, and -3 kinases both at the gene and protein level. PIM-1 was the most expressed protein, PIM-3 the least. PIM kinase levels differed between controls and disease groups, with reduced PIM-1 protein and increased PIM-3 protein in all disease samples compared to controls. No difference was found in the expression of these molecules between the three different pathologies. PIM levels were not modified after 6 months of therapy. In conclusion, our preliminary data suggest a deregulation of the PIM pathway in inflammatory arthritides. In-depth studies on the role of PIM kinases in this field are warranted.<\/jats:p>","DOI":"10.3390\/ijms25063123","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T03:52:11Z","timestamp":1709869931000},"page":"3123","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PIM Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5678-6506","authenticated-orcid":false,"given":"Elisa","family":"Assirelli","sequence":"first","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-7351","authenticated-orcid":false,"given":"Jacopo","family":"Ciaffi","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Scorcu","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Naldi","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Brusi","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Mancarella","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Lisi","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Pignatti","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ursini","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"},{"name":"Department of Biomedical and Neuromotor Sciences (DIBINEM), Alma Mater Studiorum University of Bologna, 40126 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3257-6293","authenticated-orcid":false,"given":"Simona","family":"Neri","sequence":"additional","affiliation":[{"name":"Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/med.21284","article-title":"The PIM family of serine\/threonine kinases in cancer","volume":"34","author":"Carnero","year":"2014","journal-title":"Med. Res. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: The role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.41744","article-title":"Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis","volume":"73","author":"Maney","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/art.40863","article-title":"Pim-1 as a Therapeutic Target in Lupus Nephritis","volume":"71","author":"Fu","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Walhekar, V., Bagul, C., Kumar, D., Muthal, A., Achaiah, G., and Kulkarni, R. (2022). Topical advances in PIM kinases and their inhibitors: Medicinal chemistry perspectives. Biochim. Biophys. Acta Rev. Cancer, 1877.","DOI":"10.1016\/j.bbcan.2022.188725"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0092-8674(84)90309-X","article-title":"Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region","volume":"37","author":"Cuypers","year":"1984","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rathi, A., Kumar, D., Hasan, G.M., Haque, M.M., and Hassan, M.I. (2021). Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects. Biochim. Biophys. Acta, 1865.","DOI":"10.1016\/j.bbagen.2021.129995"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejmech.2019.03.050","article-title":"PIM kinase inhibitors: Structural and pharmacological perspectives","volume":"172","author":"Asati","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors","volume":"24","author":"Mikkers","year":"2004","journal-title":"Mol. Cell. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.7150\/jca.53134","article-title":"Protein kinase PIM2: A simple PIM family kinase with complex functions in cancer metabolism and therapeutics","volume":"12","author":"Wang","year":"2021","journal-title":"J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.biocel.2004.11.005","article-title":"The serine\/threonine kinase Pim-1","volume":"37","author":"Bachmann","year":"2005","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.biocel.2017.10.016","article-title":"PIM kinases: From survival factors to regulators of cell motility","volume":"93","author":"Santio","year":"2017","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4161\/isl.2.5.13058","article-title":"Pim3 negatively regulates glucose-stimulated insulin secretion","volume":"2","author":"Vlacich","year":"2010","journal-title":"Islets"},{"key":"ref_14","first-page":"4085","article-title":"The role of Pim kinase in immunomodulation","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2567.2010.03286.x","article-title":"Proviral integration site 2 is required for interleukin-6 expression induced by interleukin-1, tumour necrosis factor-alpha and lipopolysaccharide","volume":"131","author":"Yang","year":"2010","journal-title":"Immunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/rheumatology\/key261","article-title":"PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes","volume":"58","author":"Ha","year":"2019","journal-title":"Rheumatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cellimm.2011.10.011","article-title":"The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease","volume":"272","author":"Jackson","year":"2012","journal-title":"Cell. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"58872","DOI":"10.18632\/oncotarget.19438","article-title":"Inflammation and stem markers association to PIM1\/PIM2 kinase-induced tumors in breast and uterus","volume":"8","author":"Ferrer","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/joim.12395","article-title":"Human autoimmune diseases: A comprehensive update","volume":"278","author":"Wang","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102421","DOI":"10.1016\/j.jaut.2020.102421","article-title":"Systemic autoinflammatory diseases","volume":"109","author":"Krainer","year":"2020","journal-title":"J. Autoimmun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): Updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Yin, G., Li, Y., Yang, M., Cen, X.M., and Xie, Q.B. (2015). Pim-2\/mTORC1 Pathway Shapes Inflammatory Capacity in Rheumatoid Arthritis Synovial Cells Exposed to Lipid Peroxidations. Biomed. Res. Int., 2015.","DOI":"10.1155\/2015\/240210"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1136\/annrheumdis-2014-205850","article-title":"IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anticitrullinated peptide antibody-negative rheumatoid arthritis","volume":"75","author":"Anderson","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/rheumatology\/kez003","article-title":"Expression of STAT3-regulated genes in circulating CD4+ T cells discriminates rheumatoid arthritis independently of clinical parameters in early arthritis","volume":"58","author":"Anderson","year":"2019","journal-title":"Rheumatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2011-200968","article-title":"A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease","volume":"71","author":"Pratt","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1038\/s12276-022-00893-y","article-title":"Pim1 promotes IFN-beta production by interacting with IRF3","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1225160","DOI":"10.3389\/fimmu.2023.1225160","article-title":"The impact of EMA recommendations on the real-life use of Janus kinases inhibitors for rheumatoid arthritis: The Expanded Risk Score in RA as a tool to quantify the risk of cardiovascular events","volume":"14","author":"Favalli","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"116016","DOI":"10.1016\/j.ejmech.2023.116016","article-title":"Targeting PIM kinases in cancer therapy: An update on pharmacological small-molecule inhibitors","volume":"264","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.ygeno.2020.10.001","article-title":"Discovery and in silico evaluation of aminoarylbenzosuberene molecules as novel checkpoint kinase 1 inhibitor determinants","volume":"113","author":"Singh","year":"2021","journal-title":"Genomics"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"7693","DOI":"10.1080\/07391102.2021.1900918","article-title":"Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: An in silico exploration","volume":"40","author":"Singh","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1074\/jbc.M208246200","article-title":"Protein phosphatase 2A regulates the stability of Pim protein kinases","volume":"278","author":"Losman","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1158\/1541-7786.MCR-04-0192","article-title":"Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway","volume":"3","author":"Shay","year":"2005","journal-title":"Mol. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"113469","DOI":"10.1016\/j.celrep.2023.113469","article-title":"PIM kinases regulate early human Th17 cell differentiation","volume":"42","author":"Buchacher","year":"2023","journal-title":"Cell Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"22412","DOI":"10.18632\/aging.203547","article-title":"Pim-2 kinase inhibits inflammation by suppressing the mTORC1 pathway in atherosclerosis","volume":"13","author":"Liao","year":"2021","journal-title":"Aging"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prp.2017.01.018","article-title":"Up-regulation of Pim-3 in Chronic Obstructive Pulmonary Disease (COPD) patients and its potential therapeutic role in COPD rat modeling","volume":"213","author":"Yang","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1228874","DOI":"10.3389\/fmed.2023.1228874","article-title":"Building a rheumatology biobank for reliable basic\/translational research and precision medicine","volume":"10","author":"Assirelli","year":"2023","journal-title":"Front. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3123\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:10:47Z","timestamp":1760105447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/6\/3123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["ijms25063123"],"URL":"https:\/\/doi.org\/10.3390\/ijms25063123","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]}}}